RAPT Therapeutics Reports Positive Phase 2 Trial Results

RAPT Therapeutics ( (RAPT) ) just unveiled an update.

On October 20, 2025, RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Co., Ltd. announced positive results from a phase 2 trial of RPT904 for chronic spontaneous urticaria. The trial showed that RPT904, administered at 8-week and 12-week intervals, demonstrated comparable efficacy and safety to omalizumab, a standard treatment dosed every 4 weeks. These findings suggest RPT904’s potential as a more convenient treatment option, prompting plans to advance to phase 3 trials and discussions with regulatory authorities. The trial involved 137 patients and highlighted RPT904’s sustained efficacy and tolerability, with no serious adverse events reported.

The most recent analyst rating on (RAPT) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.

Spark’s Take on RAPT Stock

According to Spark, TipRanks’ AI Analyst, RAPT is a Underperform.

RAPT Therapeutics’ overall stock score reflects significant challenges, primarily due to its inability to generate revenue and consistent operational losses. The strong equity position in the balance sheet is a positive, but technical indicators suggest a continued downward trend. The negative valuation metrics further highlight the risks associated with the stock.

To see Spark’s full report on RAPT stock, click here.

More about RAPT Therapeutics

RAPT Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing therapies for inflammation and oncology. The company is known for its innovative drug candidates, including RPT904, which targets chronic spontaneous urticaria and other inflammatory conditions.

Average Trading Volume: 175,778

Technical Sentiment Signal: Buy

Current Market Cap: $485.2M

Learn more about RAPT stock on TipRanks’ Stock Analysis page.